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Abstract 
Select free amino acids have been suggested to promote early satiation. Initial 
studies indicate that L-tryptophan may play an important role in reducing appetite. 
The current set of experiments examined whether dietary and intragastrically 
administered L-tryptophan decreases food consumption and whether this effect is 
specific to eating stimulated by energy (calorie) needs or by pleasant taste 
(reward). A link between a satiating action of L-tryptophan and activity of the 
anorexigenic oxytocin circuit has also been investigated. Supplementation of milk 
formula-based diets with tryptophan reduced energy deprivation-induced 
consumption of these formulas in mice. Tryptophan enrichment had no effect on 
water intake, which precludes the involvement of taste- or thirst-related 
mechanisms in tryptophan-driven hypophagia. Intragastrically administered L-
tryptophan decreased deprivation-induced chow intake. It also reduced hedonics-
driven consumption of palatable saccharin and milk, but not of sucrose solutions 
in non-deprived mice, suggesting a link with feeding reward mechanisms 
unrelated to sucrose. Finally, oxytocin receptor blockade with very low doses of 
an antagonist just prior to intragastric L-tryptophan administration, completely 
abolished early termination of deprivation-induced food intake by this amino acid. 
Overall, the data indicate that dietary supplementation and intragastric delivery of 
free L-tryptophan reduce eating behaviour stimulated by energy needs and 
palatability, and that the effect of L-tryptophan is mediated by the anorexigenic 
oxytocin system. 
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Chapter 1: Introduction 
 
1.1 Obesity and appetite 
1.1.1 The obesity epidemic 
Over the past several decades obesity has become one of the most significant 
health crises facing society on a global scale [1]. New Zealand suffers from the 
third highest rate of obesity within the OECD. In 2015, the New Zealand Health 
Survey found that almost one third of adults within New Zealand were clinically 
obese and a further third considered overweight [2]. Obesity rates within New 
Zealand are the highest in Māori and Pacific Island communities [3]. An obese 
individual carries a significantly increased risk of developing a number of 
diseases, including certain forms of cancer, type 2 diabetes and coronary heart 
disease [4]. Obesity is now one of the leading causes of preventable deaths 
worldwide, and has reached epidemic proportions within New Zealand.  
 
Weight gain occurs when overall energy expenditure is outstripped by energy 
intake [5]. A number of factors have been attributed as the cause of obesity, 
including high-stress lifestyles, changes in social attitudes towards weight and 
physical inactivity [6]. While these factors play a role in the increasing incidence 
rate of obesity, the most significant contributing environmental factor has been an 
increase in calorie consumption [7]. New Zealanders on average consume 2810 
kilocalories per day [8]. This quantity of energy intake is significantly more than 
is needed to maintain basic functions of the organism and most individuals do not 
expend excess energy through physical activity [7]. Therefore, an important 
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strategy to reduce the incidence of obesity is to decrease the average rate of 
energy intake via dietary manipulations.  
 
1.1.2 Dietary macronutrient composition 
There are numerous factors that influence food consumption. Key aspects that 
contribute to eating behaviour are associated with food characteristics. Those 
characteristics include, among others, flavour, texture, temperature, and energy 
density of a food item [9-11]. Importantly, macronutrient composition of a diet 
can have a profound impact on the perceived attractiveness as well as on satiating 
properties of a given food item [12]. Macronutrient composition of a diet thus 
represents a significant factor associated with energy intake. 
 
The variation in macronutrient composition of otherwise similar, isocaloric food 
items can impact food consumption. For example, both high-sugar and high-fat 
foods are associated with the overconsumption of calories and, ultimately, weight 
gain [13]. This is attributed two effects. Firstly, sugars and fats are perceived as 
highly palatable, improving not only the scent and flavour of food items, but also 
food texture [14]. Meats with high fat content are considered to be juicier and 
more tender [15]. Secondly, high-sugar and high-fat food items tend to enhance 
activity of neuroendocrine pathways that promote consumption (simultaneously 
suppressing activity of satiety mechanisms), thereby increasing meal volume and, 
consequently, energy intake, and shortening the time before additional food items 
are consumed [16, 17]. It is important to note that in the industrialised world, the 
most affordable  and most accessible food items also tend to contribute the most 
to weight gain, via unfavourable macronutrient composition and high energy 
 12 
 
density. These foods are high in sugars, fats and overall energy content, but low in 
nutritive quality [6] 
 
Early attempts to manipulate dietary macronutrient composition to benefit weight 
loss focused on reducing energy density of a diet, especially through minimisation 
of dietary fat content [18]. These low-energy diets promoted promising reductions 
in the body mass of participants during short-term eating behaviour studies, 
however, later long-term monitoring of individuals given these diets revealed 
issues in adherence associated with greatly reduced satiation following meals [19]. 
Since these initial investigations, a substantial body of research has been 
conducted on the effects of various macronutrient compositions on energy intake, 
satiety, appetite regulation and weight loss [20-24]. This research has repeatedly 
demonstrated the importance of macronutrient composition in relation to feeding 
behaviours. A strong consensus has emerged within the scientific literature which 
holds that of the three significant macronutrients, fats, carbohydrates and proteins, 
it is the protein content of a diet that has the most potent suppressive effect on 
energy intake and appetite.  
 
1.1.3 The effects of high-protein diets on appetite 
Macronutrients are a source of calories. Consumption of proteins and 
carbohydrates provides 4 kcal/g of energy, whereas energy-dense fats, 9 kcal/g 
[25]. In addition to ensuring that energy requirements are met, protein 
consumption serves as the sole source of exogenous amino acids [26]. Proteins are 
comprised of amino acids linked by peptide bonds, forming large polymer chains. 
During digestion, proteins are broken into amino acids before absorption within 
 13 
 
the small intestine. These amino acids are vital for numerous biological processes, 
notably, for general biosynthesis. Of 21 proteinogenic amino acids, 9 cannot be 
synthesised within the mammalian body and are considered “essential”. In order 
to prevent malnutrition, these amino acids must be obtained from a protein-rich 
diet [27].  
 
The proportion of proteins to other macronutrients in the diet has a significant 
effect on food intake [20]. High-protein diets are considered to be, based on 
average protein intake, diets in which 20-30% of total energy-intake is sourced 
from protein [22]. High-protein diets have been thoroughly demonstrated to 
enhance the development of satiety in humans and other animals, delaying the 
onset of hunger [28]. This satiating effect of protein is of a much greater 
magnitude than what has been observed after consumption of high-carbohydrate 
or high-fat diets [29].  
 
Food intake studies where humans are provided isocaloric meals rich in either 
proteins, fats or carbohydrates best illustrate the unique impact high-protein diets 
have on the development of satiety and resultant energy intake [30]. For example, 
Poppitt et al. provided subjects with identical isocaloric meals to which 1 MJ of 
either carbohydrate, fat or protein was discretely added. Subjects unknowingly 
given protein-enriched meals had the lowest energy intakes, as well as the lowest 
self-reported levels of hunger following meal consumption [31]. 
 
Short-term feeding studies have demonstrated that even single meals containing a 
high proportion of  protein can alter post-meal perceptions of hunger [32, 33]. 
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Isocaloric breakfasts with high fat, protein or carbohydrate compositions were 
provided to subjects in a single-meal study conducted by Stubbs et al. Participants 
who consumed high-protein breakfasts demonstrated the highest rates of post-
meal satiety of all groups [30].  Even snacks differing in protein content, when 
consumed between meals, impacted subsequent energy-intake [34, 35]. Ortinau 
and colleagues found high-protein yoghurt snacks, in comparison to nearly 
isocaloric high-fat cracker and chocolate snacks, delayed the onset of hunger and 
led to reduced energy intake during a subsequent meal [36]. Several long-term 
dietary trials have corroborated these results, and have shown that increasing the 
proportion of protein within the diet can lead to successful long-term weight loss 
[37, 38]. For example, Leidy et al. placed obese and pre-obese women on two 
varieties of 750 kcal/d energy-deficit diets, a normal-protein diet (18% protein) 
and a high-protein diet (30% protein). These diets were maintained for a 12 week 
period. The high-protein diet aided participants in preserving lean body mass 
during weight loss. More importantly, this diet was found to induce higher satiety 
levels throughout the course of the study, leading to consistently higher self-
reported satisfaction [39]. 
 
While the appetite suppressing effects of high-protein diets have been 
convincingly demonstrated in animal and human models, the exact mechanism by 
which these diets induce satiety is currently unknown [22]. Even short-term high-
protein diets effect the function of various components of the body, including the 
gastrointestinal, endocrine and neural system [40]. As a result, there are a number 
of potential physiological mechanisms by which high-protein diets may induce 
satiety and reduce energy-intake [41]. Key among these mechanisms are an 
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increased energy expenditure via diet-induced thermogenesis (DIT), increased 
levels of gluconeogenesis, increased production of satiety hormones, reduced 
sensory attractiveness and increased blood plasma amino acid concentrations [22]. 
1.1.3.1 Dietary-induced thermogenesis 
Processing and incorporating food from the diet into the body via digestion, 
absorption and various metabolic pathways leads to a temporary increase in 
energy expenditure. This effect, termed dietary-induced thermogenesis, is 
measured as the percentage increase in energy expenditure above resting 
metabolic rate [42]. 
 
The comparatively more complex structure and components of dietary proteins 
make them harder to be digested and absorbed than carbohydrates or fats, and thus 
digesting proteins requires significant energy [43]. Proteins, as a result, have a 
significantly higher DIT value than either carbohydrates or fats. The DIT values 
of proteins, carbohydrates and fats have been reported as 20-30%, 5-10% and 0-3% 
respectively [44].  
 
As such, even when consuming equal portions of isocaloric meals, the 
macronutrient composition of that meal will directly affect overall energy-intake, 
by changing the amount of energy required for meal digestion and absorption [45]. 
High-protein diets have been shown to cause an increase in resting metabolic rates 
in humans [46]. Mikkelsen et al. demonstrated that the substitution of 18% of 
dietary carbohydrate with protein caused an measurable increase in 24-hour 
energy expenditure [47].  
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The high DIT of protein, in addition to increasing energy expenditure, is argued 
by some to play a role in the development of satiety [22]. One proposed 
mechanism by which this could occur is via an increased oxygen demand during 
protein digestion and absorption. This increased oxygen demand has been 
suggested to act in a manner resembling appetite suppression observed at high 
altitude [48]. Another proposed mechanism is through the increased body 
temperature resulting from DIT translating in some manner to feelings of satiety 
[42].  
1.1.3.2 Gluconeogenesis 
The production of glucose via gluconeogenesis has a notable impact on the 
development of satiety [49]. Increasing glucose levels within the plasma directly 
suppresses appetite through physiological systems acting to prevent 
hypoglycaemia [50]. Consuming a high protein diet, especially in combination 
with low carbohydrate intake, has been shown to promote gluconeogenesis within 
the liver [51]. Rats fed solely high-protein diets demonstrate increased levels of 
key enzymes (glucose-6-phosphate and phosphoenolpyruvate carboxykinase) 
associated with gluconeogenesis [52]. Human subjects fed high-protein diets 
exhibit increased levels of gluconeogenesis. This was shown in a recent study by 
Veldhorst et al., which, however, also found heightened gluconeogenesis 
associated with high-protein diets did not directly impact the development of 
satiety [53]. Instead this gluconeogenesis lead to increased production of ketones 
such as beta-hydroxybutyrate which are now suspected to be playing a role in 
appetite suppression [54]. 
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1.1.3.1 Satiety hormones 
There are a many hormones that are synthesised within the gut that play 
significant roles in digestion and gastric function [55]. These hormones are often 
synthesised in response specific dietary intake. For example, glucagon-like 
peptide-1 (GLP-1) is an incretin which induces the release of insulin in response 
to dietary glucose [56]. GLP-1 also inhibits gastrointestinal secretion and overall 
motility, playing an important role in the development of satiety and appetite [57]. 
Cholecystokinin (CCK) is another hormone synthesised within the gastrointestinal 
tract which impacts digestive activity, largely by inhibiting gastric emptying, 
inducing gallbladder contraction and stimulating pancreatic enzyme release [58]. 
CKK also stimulates the vagal afferent pathway that originates from the 
gastroduodenal mucosa [59]. Studies have shown that humans have an increased 
peripheral secretion of both GLP-1 and CKK following even a short-term 
consumption of a high-protein diet [60, 61]. This suggests that some component 
of high-protein diets induces satiety through increased synthesis of hormones 
which play a role in delaying the digestive process and decreasing gastric 
emptying. Furthermore, it has also been shown that the consumption of  high-
protein diets in contrast to isocaloric high carbohydrate diets leads to a decrease in 
concentrations of orexigenic hormones, including ghrelin [62]. 
1.1.3.2 Reduced sensory appeal 
A significant drawback to increasing the protein content of the diet is the 
association between high levels of dietary protein and increased levels of sensory-
specific satiety [32]. High-protein food items are perceived as less palatable than 
high-carbohydrate or high-fat items, leading to a much faster decline in the 
pleasure of  ongoing food consumption [63]. While this accounts for some of the 
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appetite inhibiting behaviour induced by high-protein diets, it also leads to a lack 
of diet regimen compliance [64]. This is especially an issue for manufacturers of 
foods aimed at health-conscious consumers, as a fine balance must be struck 
between nutritive value and the desirability of the product itself [65]. By reducing 
the fat and carbohydrate content of food items while increasing protein content 
important factors associated with food palatability such as scent, taste, appearance 
and texture are altered unfavourably [66].  
 
Protein-induced decreases in palatability have been shown in food products 
ranging from sausage meat [67] to rice snacks [68] to yogurt [34]. (Even attempts 
to overcome this effect through modern food technology, such as specialised high-
protein frankfurter sausages created by Siversten and colleagues, have produced 
disappointing outcomes as the food items have been described as less juicy, 
harder and more granular than their low-protein counterparts [65] This can lead to 
rejection of the product in favour of less protein-dense counterparts [69].  
Siversten et al. predict that, with the application of modern food making 
techniques, inclusion of vegetable based oils and the addition of flavouring such 
as MSG, the protein content of meat-based food items similar to frankfurter 
sausages could be increased to approximately 40% before palatability becomes an 
unacceptable factor for consumers [65]. 
1.1.3.3 Component amino acids 
It should be emphasized that proteins are extremely complex molecules, differing 
in the lengths of amino acid chains and the actual content of individual amino 
acids. Ingested protein is obviously broken down in the digestion process and, 
therefore, these shorter amino acid chains as well as free amino acids– at the 
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organism level – facilitate a host of physiological responses following protein 
consumption and those responses include satiation [40]. In line with that, in 1956 
Mellinkoff et al. put forward the aminostatic hypothesis arguing that an increase 
in individual amino acid concentration in the plasma promotes satiety, whereas a 
reduction in amino acid levels leads to increased hunger [70]. Surprisingly, 
relatively little effort has been made in order to identify which specific amino 
acids (or their select combinations) might play a critical role in activating these 
satiety mechanisms.  
 
L-tryptophan is one of the candidate amino acids whose involvement in the satiety 
process has been proposed by several authors [71-74]. The sections below 
summarise the current status of our knowledge on the link between L-tryptophan 
and energy homeostasis as well as present basic facts related to the basic functions 
and biochemical fate of this amino acid in the organism. 
  
1.2 L-tryptophan 
L-tryptophan is one of 9 essential amino acids which cannot be synthesized within 
the human body [75]. Natural L-tryptophan synthesis only occurs within plants 
and some microorganisms, and hence, L-tryptophan intake is only supplied 
through dietary sources, namely the consumption of proteins [76]. The daily 
recommended intake of L-tryptophan is estimated to be 5 mg kg−1 day−1 [75].  
 
L-tryptophan serves a variety of important functions. In addition to the standard 
role amino acids play in protein biosynthesis, L-tryptophan acts as a biochemical 
precursor for a number of substances in both the peripheral and central nervous 
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systems (CNS). These include serotonin, kynurenine, melatonin and niacin, which 
have been shown to play a role in a myriad of different physiological processes, 
including learning, memory, sleep cycles, circadian rhythm, mood, sexual activity, 
social behaviours, digestive processes and the neurological regulation of appetite. 
 
After consumption and digestion of proteins, L-tryptophan and other neutral 
amino acids are absorbed through the apical membrane of intestinal enterocytes 
via the B0AT1 epithelial amino acid transport system [77]. L-tryptophan has the 
second lowest affinity for this transport system of all neutral amino acids. The 
basolateral aromatic amino acid transporter, TAT1, transports L-tryptophan and 
other neutral amino acids through the basal membrane of enterocytes, into 
peripheral cells [77]. Ultimately, L-tryptophan enters the circulatory system. 
However, in contrast to other circulating amino acids, the majority of L-
tryptophan is not transported as a free amino acid: McMenamy and Oncley 
determined that the indole ring on L-tryptophan attaches to a single binding site 
on serum albumin via Van der Waals’ forces [78]. Thus, a large proportion of L-
tryptophan within the circulatory system will travel while bound with low affinity 
to serum albumin, a unique trait among amino acids [79]. As this single albumin 
binding site is competitively targeted by free fatty acids [80] and a variety of 
drugs (e.g., salicylates, indomethacin, probenecid and chlorpromazine) [81], a 
certain proportion of circulatory pool of L-tryptophan remains unbound. Free 
circulating L-tryptophan can be later stored in the form of membrane lecithins and 
tissue proteins [82]. These represent metabolic pools of L-tryptophan which can 
be accessed if sufficient amounts of dietary L-tryptophan are not consumed for a 
limited time period. 
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Modifications of dietary L-tryptophan intake have been shown to alter the levels 
of circulating L-tryptophan [83]. Differences in overall protein intake have a 
notable effect on the plasma concentrations of all amino acids, including L-
tryptophan [40]. For example, Fernstom et al demonstrated significant differences 
in L-tryptophan plasma levels in people consuming a total of 0 g, 75 g or 150 g of 
egg-based protein each day. These diets produced pronounced differences within 
three days of a consumption period, altering diurnal levels of circulating amino 
acids [84]. Furthermore, episodic (single-event) consumption of specific L-
tryptophan-enriched proteins has been shown to drive large transient increases in 
L-tryptophan plasma levels in people [85]. A long-term feeding study in rats, 
conducted by Feurté et al., showed that animals fed a diet high in alpha-
lactalbumin, a protein rich in L-tryptophan, had a 40% higher ratio of plasma L-
tryptophan to other amino acids [86]. Direct supplementation of the diet with free 
L-tryptophan also proportionally increases the concentration of plasma L-
tryptophan. Green et al. drew a direct linear relationship between oral loads of free 
L-tryptophan and circulating L-tryptophan levels [87]. In a similar manner, the 
intragastric administration of L-tryptophan to animals has been demonstrated to 
increase L-tryptophan concentrations in plasma [88, 89]. 
 
Overall, this large body of research has led to a consensus that dietary fluctuations 
in L-tryptophan content have a profound influence on the actual concentration of 
this amino acid in the plasma [90], and this relationship is apparent regardless of 
whether L-tryptophan is given as a free amino acid or via consumption of high-
tryptophan complex protein meals. 
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1.2.1 Peripheral utilisation of L-tryptophan 
Once taken up by the body, L-tryptophan is subject to a number of metabolic fates, 
both peripherally and in the CNS. Peripheral utilisation of L-tryptophan accounts 
for the vast majority of dietary L-tryptophan [91], which enters three key 
metabolic pathways: protein synthesis, the kynurenine pathway and the serotonin 
pathway. 
1.2.1.1 Protein synthesis 
Despite the fact that the dietary sources of L-tryptophan are the only means for 
this amino acid to become part of protein synthesis in mammals, there is quite a 
bit of uncertainty within the scientific literature as to what proportion of dietary L-
tryptophan is later incorporated into protein synthesis [91]. A comprehensive 
review of L-tryptophan studies by J. C. Peters held that a vast majority of dietary 
L-tryptophan (approximately 90%) was utilised in the formation of proteins [92]. 
More recently, using in vitro enzyme determination to study L-tryptophan’s 
various metabolic pathways in a number of mammalian species, Allegri et al. 
argued that protein synthesis accounted for approximately 30% of dietary L-
tryptophan [93]. While this exact proportion is debated, it is known that if plasma 
L-tryptophan levels are low, L-tryptophan acts as the rate-limiting amino acid for 
the synthesis of some proteins [94]. Sidransky and colleagues compared the rate 
of hepatic protein synthesis in mice fed a balanced mixture of amino acids versus 
fasting mice given solely dietary L-tryptophan. They found that L-tryptophan 
consumption enhanced hepatic protein synthesis to a rate similar to mice fed a 
balanced mixture of amino acids. Other single amino acids, such as isoleucine, 
threonine and methionine, did not produce this effect [95]. 
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1.2.1.2 Kynurenine  
The kynurenine pathway represents another significant metabolic fate for 
peripheral L-tryptophan [91]. This pathway is likely the largest source of L-
tryptophan catabolism [92]. It should be noted that this pathway is the main 
system by which L-tryptophan plasma concentrations are regulated. The first step 
of the kynurenine pathway involves the oxidisation of L-tryptophan by tryptophan 
2,3-dioxygenase (TDO), an enzyme localised almost entirely within the liver [96]. 
This initial, rate-limiting step, first discovered by Kotake and Masayama, is 
responsible for removing excess unbound L-tryptophan from the circulation [97]. 
In fact, within a few hours of a large intake of dietary L-tryptophan, expression 
and activity of TDO can be increased four- to ten-fold [96]. While hepatic TDO is 
the only enzyme which acts solely to oxidise L-tryptophan in this manner, it is not 
the only enzyme to have this function. Another is indoleamine 2,3-dioxygenase 
(IDO), which is expressed in a range of peripheral tissues, particularly in the small 
intestine. Yamazaki et al. demonstrated IDO oxidises a wider range of substrates 
than TDO, including 5-HT, 5-HTP, tryptamine and L-tryptophan [98]. IDO is 
equally capable of oxidising L-tryptophan during the first step of the kynurenine 
pathway.  
 
The peripheral kynurenine pathway converts L-tryptophan into a wide variety of 
metabolites, with a range of functions [99]. Primarily, L-tryptophan is converted 
into quinolinic acid and nicotinamide [100], while smaller side chains of the 
pathway generate kynurenic acid and xanthurenic acid [101]. These metabolites 
are notable in inducing a variety neuroprotective and neurotoxic effects in the 
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CNS, associated with pathologies such as cataracts, dementia and brain injuries 
due to ischemia [102]. Nicotinamide and nicotinic acid are both metabolites of the 
kynurenine pathway in the liver. These substances act as precursors 
for nicotinamide adenine dinucleotide (NAD+), a ubiquitous enzyme that plays a 
critical role in many redox reactions [103]. Another product of the kynurenine 
pathway is picolonic acid, which acts as a chelating agent, in addition to aiding 
the absorption of dietary zinc [104]. 
 
Kynurenine metabolites are increasingly thought to regulate gastrointestinal 
functions, and hence impact appetite, although the exact function of most 
metabolites in this regard is still unknown [91]. Kynurenic acid in particular has 
been found to regulate gastrointestinal motility by acting as an antagonist of N-
methyl-d-aspartate (NMDA) glutamate receptors. This was well demonstrated by 
Kaszaki et al., who administered mechanical colonic obstructions to dogs before 
infusing experimental groups with 50 mg kg-1 of kynurenic acid. Animals 
administered kynurenic acid demonstrated a major reduction in the motility 
response of obstruction-induced colonic contractions [105]. By antagonizing 
NMDA receptors, kynurenic acid also modulates the mechanosensitivity of both 
tension and mucosal vagal afferents within the gastrointestinal tract [106].  
 
L-kynurenine is an intermediate for all kynurenine metabolites within the 
kynurenine pathway. This metabolite of L-tryptophan can itself enter and be 
transported in circulation. L-kynurenine in circulation can be transported across 
the BBB by a neutral amino acid carrier [106]. Peripherally formed L-kynurenine 
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accounts for approximately 60% of the L-kynurenine involved in the kynurenine 
pathway of the CNS [107].  
1.2.1.3 Serotonin 
The remaining key metabolic fate for peripheral L-tryptophan is the serotonin 
pathway, accounting for 1-2% of overall dietary L-tryptophan [104]. L-tryptophan 
acts as a biochemical precursor for the formation of serotonin. Peripheral 
serotonin accounts for approximately 95% of total serotonin content within the 
body, the vast majority of which is located in the gut [108]. Over 90% of this 
serotonin can be found in the intestinal enterochromaffin cells [109]. Much of the 
remainder is contained within serotonergic neurons of the enteric nervous system 
[110].  
  
L-tryptophan is converted into serotonin in two steps. The first, rate-limiting step 
occurs when L-tryptophan undergoes hydroxylation via tryptophan hydroxylase 
(TPH). The product of this hydroxylation, 5-hydroxytryptophan, undergoes 
decarboxylation via aromatic acid decarboxylase, which leads to the formation of 
serotonin [83]. While the latter enzyme is ubiquitous, expression of TPH is 
localised to pinealocytes of the pineal gland, neuroendocrine epithelial cells of the 
lungs, enterochromaffin cells of the intestines, mononuclear leukocytes and 
neurons [108]. 
  
Until recently, it has been thought that TPH was encoded by a single gene. In 
2003, Côté et al.  discovered that there are in fact two isoforms of tryptophan 
hydroxylase, TPH1 and TPH2, encoded by two distinct genes [111]. Côté and 
colleagues produced a tph1 knock-out mouse which at the time was intended to 
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inhibit all serotonin synthesis. Instead, by knocking out tph1 without affecting the 
function of the then-unknown tph2 gene, they developed a mouse model 
displaying typical neuronal serotonin activity while being devoid of peripheral 
serotonin [111].   
 
Since this discovery, the localisation and functions of TPH1 and TPH2 have been 
well defined [112, 113]. TPH1 is localised to peripheral tissues, including 
pinealocytes and neuroendocrine lung cells [111]. Most significantly, TPH1 is 
strongly expressed in the enterochromaffin cells of the intestine, in which the vast 
majority of serotonin is synthesised and stored [91]. TPH2 is present solely in 
neurons. This includes the small proportion of serotonergic neurons in the enteric 
nervous system, which contribute a much smaller proportion of peripheral 
serotonin [114]. 
 
Enterochromaffin cells are one of 14 kinds of specialised enteroendocrine cells 
within the intestines, which synthesize serotonin from L-tryptophan, storing it in 
intracellular vesicles [115]. These cells play a critical role in sensing and 
signalling both mechanical and chemical stimuli in the intestines [116]. Changes 
to luminal pressure due to the movement of food boluses through the intestines 
directly activate enterochromaffin cells [117]. Additionally, enterochromaffin 
cells are activated by a variety of chemical stimuli including changes in pH, the 
presence of bile acid and dietary glucose [115]. Activation of enterochromaffin 
cells induces the extracellular release of serotonin, which has two important 
physiological effects. Firstly, this serotonin acts to stimulate intrinsic primary 
afferent neurons belonging to the enteric nervous system [108]. In doing so, 
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gastrointestinal motor activity and secretory processes critically important to 
digestion are coordinated, both intrinsically via the enteric nervous system, and 
extrinsically [118]. Secondly, serotonin originating from enterochromaffin cells 
directly effects the central nervous system through the activation of vagal 
afferents projecting to the hindbrain [119]. 
 
The serotonergic neurons of the enteric nervous system represent a smaller source 
of peripheral serotonin synthesis. Small pockets of interneurons within the enteric 
nervous system not only receive serotonin signal input, but are themselves capable 
of synthesising and releasing serotonin externally [91]. 
1.2.2 Uptake of L-tryptophan into the central nervous system 
In addition to peripheral L-tryptophan utilisation, L-tryptophan functions as a 
biochemical precursor for a number of metabolic pathways within the CNS, many 
of which produce neuroactive substances closely associated with the regulation of 
food intake. L-tryptophan within the CNS is sourced from blood plasma, and must 
cross the blood-brain barrier.  
 
Both the plasma concentrations of L-tryptophan and the plasma concentrations of 
a number of other large, neutral amino acids (LNAAs), such as phenylalanine, 
leucine, tyrocine, isoleucine and valine, are directly responsible for the rate of 
uptake of L-tryptophan into the brain [120]. This process is mediated by the 
transport mechanism which enables these substances to cross the blood-brain 
barrier (BBB), the large neutral amino acid transporter (LAT1) [121]. LAT1 is a 
membrane transport protein highly expressed within the capillary endothelia of 
the BBB [122]. LAT1 transport of LNAAs is a process that is both saturable and 
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competitive. The affinity of LAT1 is similar across all associated LNAAs, and 
competition for transport is based largely on the total LNAA plasma 
concentrations [123]. Thus, the rate of uptake of L-tryptophan into the brain can 
be increased with the increase of total L-tryptophan plasma concentrations, or 
increased by reducing plasma concentrations of all other LNAAs competing for 
transport [121]. 
 
Various aspects of dietary intake can alter the rate at which L-tryptophan is 
transported across the BBB by LAT1 [124]. Simply increasing the proportion of 
dietary L-tryptophan intake increases L-tryptophan BBB transport [125]. Choi et 
al. demonstrated that chronic intake of different proteins with various L-
tryptophan content, including wheat gluten, soy protein, casein, or α-lactalbumin, 
significantly altered L-tryptophan levels in the central nervous system of rats 
[126]. High-carbohydrate diets have also been shown to significantly enhance L-
tryptophan BBB transport. Madras et al. demonstrated that the consumption of a 
carbohydrate rich diet by young rats acted to increase the transport of L-
tryptophan into the CNS [127]. This effect has been attributed to an increase in 
insulin production. Biolo et al. conducted a series of biopsies on fatigued human 
leg muscles  following infusions of insulin [128]. Increased insulin levels were 
found to promote the movement of amino acids from the circulatory system into 
the body tissues, especially muscle fibres, for use in protein synthesis. In doing so, 
insulin significantly reduces the circulatory concentrations of all LNAAs except 
L-tryptophan, as the large proportion of L-tryptophan bound to serum albumin is 
not removed from circulation [129]. Lipsett and colleagues established this 
through a study which carefully measured circulating L-tryptophan levels in 
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humans following glucose ingestion [130]. Participants consumed various 
quantities of a ligand competitive for L-tryptophan’s albumin binding site, and 
hence developed differing ratios of albumin-bound to free L-tryptophan. 
Following the actions of insulin, only the albumin-bound pool of L-tryptophan 
remained in the plasma [130]. 
  
This albumin-bound L-tryptophan can be accessed by LAT1 [131]. A series of in 
vivo experiments on rat and rabbit brains by Pardridge  and Fierer aiming to 
determine the disassociation constant of albumin binding to free L-tryptophan 
ultimately showed that L-tryptophan crossing the BBB was drawn not only from 
free L-tryptophan but also from the larger pool of albumin-bound L-tryptophan 
via an enhanced disassociation mechanism present at the BBB [132]. The action 
of insulin following carbohydrate intake increases the ratio of L-tryptophan in 
circulation to all other LNAAs [133]. This significantly increases the quantity of 
L-tryptophan transported across the BBB by LAT [127]. In contrast, a diet rich in 
proteins without high L-tryptophan content can boost plasma concentrations of 
alternative LNAAs, decreasing the ratio of L-tryptophan to other LNAAs, 
reducing L-tryptophan BBB transport  [85]. 
 
After crossing the blood-brain barrier, L-tryptophan enters the extracellular fluid 
of the CNS, where it is taken up by brain cells [131]. The rate of circulatory L-
tryptophan transport across the blood-brain barrier by LAT1 controls the levels of 
L-tryptophan within the brain [134]. The availability of L-tryptophan in the brain 
to act as a biochemical precursor has been shown to directly drive brain L-
tryptophan metabolite synthesis, such as the synthesis of serotonin [135]. 
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1.2.3 Central nervous system utilization of L-tryptophan 
There are a number of metabolic fates for L-tryptophan within the CNS that can 
impact the regulation of appetite and other important biological functions. As in 
the periphery, one of the main utilizations of CNS L-tryptophan is for general 
protein synthesis [83], however, there are three other significant metabolic 
pathways. These are the kynurenine pathway, the serotonin pathway and the 
melatonin pathway.    
1.2.3.1 Kynurenine  
By quantity, the kynurenine metabolic pathway within the CNS represents the 
largest utilization of CNS L-tryptophan after protein formation, accounting for 
over 95% of remaining CNS L-tryptophan [124]. The first steps of this pathway 
are active in most cell types within the CNS, including neurons, astrocytes and 
microglia, as well as infiltrating macrophages [136]. However, a recent in vivo 
study of rat brains by Amori et al. in which 3H-kynurenine was traced, 
demonstrated that the various kynurenine metabolites are only metabolised in 
specific cell types [137].  
 
The first step of the kynurenine pathway in the CNS, similar to what occurs in the 
periphery, involves the oxidation of L-tryptophan. Both rate-limiting enzymes 
responsible for this oxidation (the L-tryptophan specific tryptophan 2,3-
dioxygenase and the less specific indoleamine 2,3-dioxygenase) are present within 
most CNS cells [96]. L-kynurenine is an intermediate in the kynurenine pathway. 
Only 40% of the L-kynurenine utilised by the CNS is synthesised locally. The 
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remainder is drawn from circulation via the BBB, hence, peripheral L-kynurenine 
concentrations can have a direct impact on the activity of  CNS kynurenine 
metabolism [107]. 
 
Some significant neuroactive metabolites of the this metabolic pathway include 
kynurenic acid (an antiexcitotoxic) [138], picolinic acid (a neuroprotectant and 
immune modulator) [136], and quinolinic acid (a potent neurotoxin) [139]. Many 
of the functions of these metabolites are still under investigation, and the actions 
they have on the regulation of appetite and other biological processes are 
unknown [124]. Currently most research efforts are focused on the role many of 
these metabolites play in of the pathogenesis of various diseases, including several 
psychiatric disorders, Huntington’s disease, Tourette syndrome as well as 
peripheral conditions such as cardiovascular disease [140].  
1.2.3.2 Serotonin 
A second L-tryptophan metabolite within the CNS that has a vital role in many 
physiological processes is the neurotransmitter serotonin. CNS serotonin is almost 
exclusively produced in the raphe nuclei, discrete clusters of neurons, forming the 
medial portion of the reticular formation in the brain stem [141]. The neurons 
comprising the raphe nuclei are heterogeneous, with a variety of morphologies 
and characteristics, and these neurons project to various regions of the brain [142]. 
Many of these neurons are serotogenic, and it is within these nuclei that L-
tryptophan is converted into serotonin in a two-step reaction [143]. The raphe 
nuclei project extensively throughout the CNS. The median and dorsal raphe 
nuclei project throughout much of the forebrain, including the cortex, amygdala, 
hippocampus and the hypothalamus [142]. The caudal raphe nuclei project to the 
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spinal cord and brainstem, including the nucleus of the solitary tract [142]. These 
regions of the brain, especially the hypothalamus, are essential to many processes 
involved in the regulation of energy balance and appetite as well as myriad other 
physiological functions [144]. These brain regions all express a variety of 
different serotonin receptors, and serotonin input from the raphe nuclei can 
significantly alter the activity of these structures [145-147]. Furthermore, 
serotonin appears to functionally interact within wider neuropeptidergic systems 
involved in feeding control, including those associated (directly or indirectly – via 
multisynaptic pathways) with the leptin and ghrelin, as well as insulin and orexin 
[148].  
 
It was recognised as early as the 1970’s that dietary manipulations of CNS L-
tryptophan concentrations directly alter the rate at which serotonin is synthesised 
[90, 134, 149, 150]. There is convincing evidence that alteration to serotonin 
synthesis and concentration within the CNS can have a significant impact on 
overall food intake and many other ingestive behaviours, by altering the activity 
of neurological structures associated with the coordination of, and response to, 
peripheral and metabolic signals [146]. 
1.2.3.3 Melatonin 
Melatonin synthesis is another notable metabolic fate for L-tryptophan. Melatonin 
is a neurohormone produced primarily within the pineal gland, synthesised from 
L-tryptophan in a four step reaction using serotonin as an intermediary [151]. 
Unlike prior CNS metabolic pathways, L-tryptophan involved in the formation of 
melatonin does not need to cross the BBB, and is instead drawn directly from 
circulatory L-tryptophan [152].  
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One of main functions of melatonin is to entrain circadian rhythms in a number of 
key biological processes, including the sleep-wake cycle and appetite [153]. 
Melatonin synthesis in the pineal gland is largely dependent on the day-night 
cycle [151]. Visual detection of blue light, particularly around 460-480 nm, acts to 
inhibit the function of aralkylamine N-acetyltransferase, a key enzyme within the 
melatonin metabolic pathway [154]. Melatonin production in the pineal gland, as 
a result, typically occurs from dusk until dawn. 
 
Dietary manipulations of plasma L-tryptophan levels have been demonstrated to 
be capable of inducing increased pineal melatonin formation even during the 
light-phase of pineal function [155]. Broiler chickens orally administered 150 mg-
1 kg-1 of free L-tryptophan during pineal light-phase by Zeman et al. demonstrated 
enhanced melatonin production three hours following administration, however, 
this production was limited and did not significantly affect melatonin levels in the 
following dark-phase [156]. Pineal melatonin can enter into circulation, where it 
is readily drawn across the BBB and into the CNS [157]. Alternatively, melatonin 
can be released directly into the third ventricle of the CNS via the pineal recess 
[158]. CNS melatonin has a wide array of physiological functions [159], but the 
role melatonin plays in the regulation of appetite is becoming increasingly 
apparent [151]. Animal models have shown melatonin acts to inhibit food intake. 
By administering small and large doses of melatonin via water, Piccinetti and 
colleagues demonstrated that increased melatonin reduced food intake in zebrafish 
[160]. This result was attributed to stimulation of molecules that act as satiety 
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signals such as leptin, as well as a notable reduction in orexigenic signals, 
especially ghrelin [161]. 
 
1.3 L-tryptophan as a mediator of satiety  
A growing body of research supports the hypothesis that supplementary L-
tryptophan causes anorexigenic effects. Supplementing the diet with as little as 5% 
additional L-tryptophan over the course of several days decreases overall food 
intake to a degree that promotes body weight reduction [72]. Ng and Anderson 
demonstrated that direct intragastric infusions of L-tryptophan caused a decrease 
in episodic chow intake [73]. In line with those findings are the results obtained in 
a comprehensive study by Jordi et al. who administered individually via 
intragastric gavage 20 amino acids (including L-tryptophan) in food-deprived rats 
just prior to re-feeding [162]. They found that L-tryptophan generated a ca. 25% 
reduction in the amount of consumed chow, which was the fourth largest 
anorexigenic effect observed for the amino acids used in the experiments. While 
the effect was statistically significant when compared to the vehicle (p=0.03), one 
of the key problems in that project was testing the effects a very large number of 
amino acids, which precipitated the need of correcting for multiple comparisons. 
That additional correction allowed the authors to conclude that there was only a 
trend suggesting a decrease, however, they did acknowledge the similarity 
between their result and that of Ng and Anderson [73].  
Jordi et al. then went on to decipher neuronal mechanisms underlying the 
anorexigenic effects of amino acids on food intake by using c-Fos 
immunoreactivity as a marker of brain regional activation. Their analysis 
suggested that the vagal input into the brain stem plays a critical role into 
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stimulating pathways that promote satiety. In fact, they found – by using the 
amino acids that produced a statistically significant hypophagia after correction 
for multiple comparisons – that the dorsal vagal complex (DVC, especially the 
nucleus of the solitary tract (NTS) and area postrema (AP) as parts of the DVC) 
appears to serve as a common neuroanatomical platform in relaying amino acid-
derived satiation [162]. Most likely, these DVC neurons send projections to other 
brain sites, including the hypothalamus, where they activate specific neuronal 
populations involved in generating termination of food intake. Unfortunately, very 
little is known about neuropeptidergic systems mediating satiety that are activated 
by L-tryptophan. 
 
1.4. Overarching goal and specific aims of the thesis: Closing the knowledge 
gap on ingested L-tryptophan and hypophagia 
Only very initial steps in defining L-tryptophan as a hypophagic molecule have 
been undertaken: it has been shown that this amino acid decreases intake of 
standard laboratory chow and this effect is most likely mediated via pathways that 
are initiated at the brain stem (more precisely, DVC) level. Therefore, the 
current project was devised in order to provide further characterisation of L-
tryptophan’s effects on feeding and to offer a glimpse into neuropeptidergic 
mechanisms that mediate L-tryptophan-derived hypophagia. Laboratory mice 
were used throughout the studies. 
The first aim of this project focused on defining the effect of increased dietary L-
tryptophan levels on deprivation-induced intake of complex milk formula diets 
that differed in composition (skim versus regular). In order to establish whether 
amino acid-derived changes in palatability might have been the cause, the effect 
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of L-tryptophan supplementation on consumption of tryptophan-enhanced water 
was also examined. 
The second aim of this thesis defined whether an intragastric preload of L-
tryptophan affected intake driven by various stimuli, from energy deprivation to 
palatability. In this context, it should be noted that research on gastric preloads of 
L-tryptophan and appetite has revolved thus far exclusively around the issue of 
energy deprivation. It did not take into account whether this amino acid was 
capable of reducing consumption evoked by other processes, especially rewarding 
characteristics of tastants. Thus, I investigated whether L-tryptophan-evoked 
hypophagia is associated with the intake of “bland” chow or whether it extends 
upon sweet palatable tastants containing sucrose or a non-carbohydrate sweetener, 
saccharin. 
Finally, in the third aim, I sought to determine whether anorexigenic effects of L-
tryptophan are mediated by a satiety-related neurohormone, oxytocin. Oxytocin is 
a nonapeptide synthesised in the hypothalamus and released within the CNS as 
well as into the periphery (the latter occurs via posterior pituitary). One of the 
unique neuroanatomical features of oxytocin is that neurons producing it receive 
powerful input from the brain stem, including from the DVC. In fact, oxytocin is 
considered the final CNS component of vagally mediated GI signalling. As such, 
it is released upon gastric distension, an increase in plasma osmolality as well as 
upon the increase in the concentration of gut hormones in the plasma. Oxytocin 
decreases food intake driven by energy and it is also effective in reducing 
consumption for reward; antagonists of the oxytocin receptor cause an opposite 
effect. Hence, the OT system appears to be a very plausible candidate as a 
molecular component of anorexigenic pathways activated by L-tryptophan. 
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Chapter 2: Materials and Methods 
2.1 Animals 
Adult male C57BL/6 mice (AgResearch, Hamilton, NZ), body weight range 29-
33 g, were housed in individually in Plexiglas cages in a temperature controlled 
room (21-22°C) under a 12:12 light/dark cycle (lights on at 0600 h). Mice had ad 
libitum access to tap water and standard laboratory chow (Purina) unless stated 
otherwise.  
All the experiments described herein have received prior approval from the 
institutional animal ethics committee (University of Waikato AEC, Hamilton, NZ). 
 
2.2 Methods 
2.2.1 Effect of dietary L-tryptophan enrichment on deprivation-
induced intake of palatable and nutritionally adequate liquid 
diets (milk formulas) 
In order to prevent neophobia, several days prior to the beginning of experimental 
trials, mice were acclimatised to the flavour of two nutritionally adequate and 
palatable milk formulas (goat WPC+ and goat skim formula (see Table 1.)) via 
short-term, episodic exposures (at least 2x30 minutes). 
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Table 1: Composition (%) of goat WPC+ and goat skim milk formulas 
 Protein Lactose Fat Ash Moisture 
Goat WPC + 39.5 52.5 1.4 3.6 3 
Goat Skim 38.3 48.4 1 9.3 3 
 
On experimental days, the animals were deprived of chow overnight. At 1200h 
the following day, the mice (n = 7/group) were given 2-hour access to a single 
bottle containing a goat WPC+ and goat skim formula (DGC, Hamilton, NZ). 
Chow and water were not present in the cage during the time of milk presentation. 
The amount of ingested formula was measured (in grams) after 2 hours of 
consumption. The 2-h consumption time was sufficient for all the animals to 
finish their deprivation-induced consummatory activity.  
The formulas were enriched with L-tryptophan beyond levels provided in the diets 
to meet basic amino acid needs. Hence, goat WPC+ and goat skim milk formulas 
contained an additional amount of L-tryptophan in the amount exceeding base line 
levels by 0 (control), 0.036, 0.12, 0.36 or 1.2 g of L-tryptophan per liter. 
The amount of consumed diet was assessed in grams per kg of body weight. Data 
were averaged per experimental group. The effect of L-tryptophan 
supplementation on formula intake was determined with one-way ANOVA 
followed by Fisher’s post-hoc analysis (significant when P<0.05).  
 
2.2.2 Effect of enrichment of water with L-tryptophan on 
deprivation-induced drinking behaviour  
In order to determine whether adding L-tryptophan to a “neutral” ingestant affects 
its palatability and whether the effects seen with liquids diets are not driven by 
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thirst-related processes, we determined whether enrichment of water with L-
tryptophan affects drinking. Mice were deprived of water overnight (chow was 
available). At 1200h the following day, the animals (n = 7) were given L-
tryptophan-enriched water. After 2 hours, when all animals finished consumption, 
the amount of ingested fluid was measured (in grams) and converted to grams per 
kg of body weight. Tap water contained 0 (control), 0.036, 0.12, 0.36 or 1.2 g of 
L-tryptophan per liter. The effect of L-tryptophan supplementation on water 
intake was determined with one-way ANOVA followed by Fisher’s post-hoc 
analysis (significant when P<0.05). 
 
2.2.3 Effect of intragastric preload of L-tryptophan on 
deprivation-induced chow intake 
Mice were deprived of chow overnight (water was available at all times). At 
1100h the following morning, they received via intragastric gavage an infusion of 
either 0, 600, 1200 or 1800 mg/kg b. wt. of L-tryptophan (n = 7/group) in 200 µL 
of water via oral gavage. Chow was returned to cages 20 minutes later and food 
intake was measured 1, 2, 4 and 24 h after re-feeding. The effect of L-tryptophan 
preload on chow intake was determined with one-way ANOVA followed by 
Fisher’s post-hoc analysis (significant when P<0.05). 
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2.2.4 Effect of intragastric preload of L-tryptophan on saccharin 
solution intake in non-deprived mice 
In order to prevent neophobia, several days prior to the beginning of experimental 
trials, mice were acclimatised to the flavour of 0.1% saccharin solution via short-
term, episodic exposures (at least 2x30 minutes).  
On the experimental day, at 1100h, the animals received via intragastric gavage an 
infusion of either 0, 300, 600 or 1200 mg/kg b. wt. of L-tryptophan (n = 7/group) 
in 200 µL of water via oral gavage. Chow and tap water were removed from the 
cages of treated animals and the formula was given in a single bottle 20 minutes 
later. Formula intake was measured after 1 h of exposure to the tastant. The effect 
of L-tryptophan preload on formula intake was determined with one-way 
ANOVA followed by Fisher’s post-hoc analysis (significant when P<0.05). 
 
2.2.5 Effect of intragastric preload of L-tryptophan on sucrose 
solution intake in non-deprived mice 
Mice were acclimatised to 10% saccharin solution similarly to what has been 
described above for sucrose (section 2.2.4). On the experimental day, at 1100h, 
the animals received via intragastric gavage an infusion of either 0, 1200 or 1800 
mg/kg b. wt. of L-tryptophan (n = 7/group) in 200 µL of water via oral gavage. 
Chow and tap water were removed from the cages of treated animals and 10% 
sucrose solution was given in a single bottle 20 minutes later. Sucrose solution 
intake was measured after 1 h of exposure to the tastant. The effect of L-
tryptophan preload on sucrose intake was determined with one-way ANOVA 
followed by Fisher’s post-hoc analysis (significant when P<0.05). 
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2.2.6 Effect of intragastric preload of L-tryptophan on palatable 
and nutritionally adequate milk intake in non-deprived mice  
Mice were acclimatised to the milk formula similarly to what has been described 
above for sucrose (section 2.2.4). On the experimental day, at 1100h, the animals 
received via intragastric gavage an infusion of either 0, 600 or 1200 mg/kg b. wt. 
of L-tryptophan (n = 7/group) in 200 µL of water via oral gavage. Chow and tap 
water were removed from the cages of treated animals and 0.1% saccharin 
solution was given in a single bottle 20 minutes later. Formula intake was 
measured after 1 h of exposure to the tastant. The effect of L-tryptophan preload 
on milk formula intake was determined with one-way ANOVA followed by 
Fisher’s post-hoc analysis (significant when P<0.05). 
  
2.2.7 Effect of oxytocin receptor antagonist pretreatment on the 
ability of intragastric L-tryptophan to suppress deprivation-
induced chow intake. 
The mice were food-deprived overnight. Fifteen minutes prior to refeeding (at 
10:00), they received an IP injection of an OT receptor antagonist, L-368,899 at 
0.03, 0.1 and 0.3 mg/kg b. wt. (or saline vehicle). Five minutes later, the 600-mg 
dose of L-tryptophan (or vehicle) was administered intragastrically (via gavage, in 
200µL of water. Chow was returned to the hoppers and consumption was 
measured 2 hours later. Data were averaged per experimental group (n=8-9/group) 
and expressed as means +/- SEM. The effect of L-tryptophan on chow 
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consumption was established using Student's t-test. The effect of the OT receptor 
antagonist on the ability of L-tryptophan to induce hypophagia was established 
with one-way ANOVA followed by Fisher's post-hoc test (significant when 
P<0.05). 
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Chapter 3: Results 
3.1 Results 
3.1.1 Effect of dietary L-tryptophan enrichment on deprivation-
induced intake of palatable and nutritionally adequate liquid 
diets (milk formulas) 
The addition of 0.036, 0.12 or 0.36 g/L of L-tryptophan to palatable liquid diets 
demonstrated no significant difference in consumption by energy-deprived 
animals over a 2 hour period. On the other hand, addition of the highest amount of 
L-tryptophan (1.2 g/L) to the milk formulations caused a modest decrease in 
consumption regardless which liquid diet was used (Fig. 1 and 2).  
 
3.1.2 Effect of enrichment of water with L-tryptophan on 
deprivation-induced drinking behaviour  
Overnight water-deprived animals given water enriched with L-tryptophan 
displayed similarly vigorous drinking behaviour regardless of the concentration of 
the amino acid (Fig. 3).  
 
3.1.3 Effect of intragastric preload of L-tryptophan on 
deprivation-induced chow intake 
While a dose of 600 mg/kg b. wt. was not sufficient to induce an effect, the 
intragastric preload of 1200 and 1800 mg/kg b. wt. of L-tryptophan in energy-
deprived mice was found to cause a moderate decrease in chow consumption. 
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This effect was observed not only during the first hour of energy-based chow 
intake, but persisted for multiple feedings over the course of 24 hours (Fig. 4). 
 
3.1.4 Effect of intragastric preload of L-tryptophan on saccharin 
solution intake in non-deprived mice 
The intragastric preload of 600 and 1200 mg/kg b. wt. of L-tryptophan  in non-
deprived animals was found to moderately decrease the consumption of 0.1% 
saccharin solution during the first hour of feeding (Fig. 5). 
 
3.1.5 Effect of intragastric preload of L-tryptophan on sucrose 
solution intake in non-deprived mice 
Non-deprived animals administered an intragastric preload of L-tryptophan 
displayed similarly vigorous consumption of 10% sucrose solution, regardless of 
L-tryptophan dosage. No effects were seen even at the highest dosage (1800 
mg/kg b. wt.) used in these studies (Fig. 6). 
 
3.1.6 Effect of intragastric preload of L-tryptophan on palatable 
and nutritionally adequate milk intake in non-deprived mice  
 
An intragastric preload of 600 mg/kg b. wt. of L-tryptophan in non-deprived 
animals was not sufficient to induce a significant effect on the consumption of 
skim goat milk formula. However, a dosage of 1200 mg/kg b. wt. of L-tryptophan 
was found to modestly decrease the consumption of this palatable liquid diet 
during the first hour of feeding (Fig.7). 
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3.1.7 Effect of oxytocin receptor antagonist pretreatment on the 
ability of intragastric L-tryptophan to suppress deprivation-
induced chow intake. 
The intragastric administration of 600 mg/kg b. wt. L-tryptophan was found to 
significantly decrease the consumption of standard chow. The IP administration of 
0.03 mg/kg b. wt. OTA had no significant impact on this effect, however, the IP 
administration of 0.1 and 0.3 mg/kg b. wt. of OTA had a significant impact on the 
anorectic effect of intragastric L-tryptophan, returning chow consumption to near 
baseline levels (Fig. 8). 
 
 
Figure 1: L-tryptophan added to the WBC+ milk formulation in energy-deprived 
mice decreases milk consumption at 1.2 g/L. Amounts of L-tryptophan are defined on 
the X axis (per 1 l of fluid). * P < 0.05 
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Figure 2: L-tryptophan added to the skim milk formulation in energy-deprived mice 
decreases milk consumption at 1.2 g/L. Amounts of L-tryptophan are defined on the X 
axis (per 1 l of fluid). * P < 0.05 
 
Figure 3: L-tryptophan added to drinking water in water-deprived mice did not 
affect water consumption. Amounts of L-tryptophan are defined on the X axis (per 1 l 
of fluid). * P < 0.05 
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Figure 4: Intragastric preload of L-tryptophan in food-deprived mice reduces chow 
consumption at 1200 and 1800 mg/kg b. wt., 1 and 24 hours after administration. 24-
hour energy deprived mice received infusions of 0, 600, 1200 or 1800 mg/kg b. wt. of L-
tryptophan within 200 µL of saline. * P < 0.05 
 
 
Figure 5: Intragastric preload of L-tryptophan in non-deprived mice reduces 0.1% 
saccharine consumption at 600 and 1200 mg/kg b. wt. 1 hour after administration. 
Non-deprived mice received infusions of 0, 300, 600, or 1200 mg/kg b. wt. of L-
tryptophan within 200 µL of saline. * P < 0.05 
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Figure 6: Intragastric preload of L-tryptophan in non-deprived mice did not affect 
10% sucrose consumption 1 hour after administration. Non-deprived mice received 
infusions of 0, 1200 or 1800 mg/kg b. wt. of L-tryptophan within 200 µL of saline. * P < 
0.05 
 
 
Figure 7: Intragastric preload of L-tryptophan in non-deprived mice reduces 
palatable milk formula consumption at 1200 mg/kg b. wt. 1 hour after 
administration. Non-deprived mice received infusions of 0, 600 or 1200 mg/kg b. wt. of 
L-tryptophan within 200 µL of saline. * P < 0.05 
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Figure 8: Oxytocin receptor antagonist pretreatment suppresses the 
anorexigenic effects of intragastric L-tryptophan. Mice received IP injections 
of oxytocin receptor antagonist L-368,899 at a dose of 0, 0.03, 0.1 or 0.3 mg/kg b. 
wt. Mice then received an intragastric infusion of 0 or 600 mg of L-tryptophan 
within 200 µL of water prior to refeeding.
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Chapter 4: Discussion 
While the neuroendocrine processing of hunger, satiety and reward plays a 
fundamental role in shaping consumption [163], food characteristics serve as the 
key factors directly modifying physiological parameters that underlie appetite. 
Foods differ in, to name a few, appearance (size, shape, colour, consistency), 
texture, flavour; microbial content, temperature, and macronutrient composition. 
All these seemingly minute details can have a profound influence on the 
motivation to seek a given food, how much of this food is eaten, how palatable it 
is and whether the feeling of “fullness” after a meal persists for a longer or shorter 
period of time. Even very basic approaches, in which simple tastants are offered 
or simple modifications to composite tastants are introduced, show surprisingly 
profound effects. For example, strong preference for a sugar solution is eliminated 
if a choice between a tasty room-temperature sucrose drink versus cold water is 
given to a thirsty individual (human or laboratory animal) [164]. The size of fibre 
molecules affects palatability of standard dog diets, with large sugarcane fibre 
particles being preferred over the small particles [165]. Presenting a diet in a 
powdered rather than pelleted texture greatly reduces preference for this diet even 
though no changes to the composition have been introduced [166]. Despite the 
myriad of characteristic features that affect acceptability and liking of food items, 
we are far from understanding the true complexity of the intertwined mechanisms 
that link food characteristics and food intake.  
The current project focused on deciphering the effect of a free amino acid, L-
tryptophan, acting intraorally and intragastrically on appetite regulation. The 
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interest in L-tryptophan (and amino acid control of eating behaviour, in general) 
as a dietary component stems from the fact that foods contain amino acids in a 
free form as well bound in proteins, peptides and non-peptide polymers [167].  
Therefore, individual amino acids are an essential contributor to food 
characteristics as they are able to affect appetite from the very early stages of 
consumption rather than – as presumed earlier – after complex proteins have been 
reduced to amino acids through the digestion process. In line with that, the 
assumption that the satiating effect of protein comes from only the complex 
protein molecule seems premature as some individual amino acids may in fact 
have the capacity to mediate hypophagia and – thus – they may act as an 
additional yet individual anorexigenic stimulus accompanying protein intake. 
This thesis represents the effort of closing the knowledge gap surrounding the 
purported anorexigenic effects of ingesting dietary L-tryptophan. This project 
aimed to do so in three ways. Firstly, through defining the effect of dietary L-
tryptophan levels within complex liquid diets on energy deprivation-induced 
intake, as well as establishing if any observed effect was related to flavour and/or 
thirst. Secondly, via investigating the effects of intragastric L-tryptophan preload 
on the consumption of palatable tastants which varied in energy density. Finally, 
by determining whether any L-tryptophan-induced hypophagia might be mediated 
at the neuroendocrine level by the anorexigenic neurohormone oxytocin. 
 
Only a select few feeding studies conducted thus far have investigated the impact 
of adding supplementary L-tryptophan to the diet [72, 168]. These earlier studies 
have demonstrated that hypophagia ensues after the amino acid supplementation. 
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However, one of the drawbacks of the initial reports was that they focused on 
defining the effect of L-tryptophan on energy dense yet “bland” chow. In the 
current project, instead of studying the effect of this amino acid on standard chow 
intake, two liquid diets based on the goat milk formula were chosen. While the 
two complex milk formula diets used in these experiments were calorically and 
nutritionally adequate, in addition to being more palatable than standard (bland) 
chow, the two diets differed in composition (Table 1), palatability and energy 
content. WPC+ goat formula, having a higher fat and lactose content than skim 
goat formula, was the more energy-dense and palatable of the two. This was 
reflected in the levels of deprivation-induced formula consumption – animals 
consumed roughly 50% more WPC+ formula than skim formula when presented 
with liquid diets unadulterated by L-tryptophan addition (Figs. 1 and 2). Despite 
the differences in the composition and gustatory quality of those two foods, L-
tryptophan supplementation had a very similar impact on the their consumption. 
Energy-deprived animals fed the milk formula with an additional 1.2 g/L of L-
tryptophan content consumed less than those fed unadulterated formula. As 
animals were deprived of food for 24 hours prior to the experimentation, this 
consumption can be largely attributed to energy needs as opposed to reward-
mediated behaviour [169]. The results of this experiment confirm the 
anorexigenic effect of dietary L-tryptophan, corroborating the findings by Ayaso 
et al [72]. These results also demonstrate for the first time that L-tryptophan 
supplementation decreases consumption of food items that differ in their 
palatability and energy density characteristics: aside for the “bland” highly caloric 
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chow, the amino acid reduces intake of two milk formulas differing from each 
other in palatability and energy density.  
 
While increases to the dietary content of L-tryptophan in the milk formula caused 
a modest decrease in formula consumption by energy-deprived animals, this 
anorexigenic effect could be potentially attributed to either a direct impact on the 
palatability of the diet or alterations in thirst-related physiological processes. A 
decrease in formula consumption could theoretically occur if, for example, high-
level L-tryptophan supplementation simply caused an unpleasant flavour in the 
liquid diets. One could argue that a decrease in formula consumption would 
likewise be possible if L-tryptophan induced a lowered drive to drink water rather 
than because of any impact on appetitive processes. In order to investigate this 
issue, a “neutral” ingestant, regular drinking water, was supplemented with L-
tryptophan in an identical manner to the previous milk formulas. As with the 
liquid diets, overnight water-deprived animals were given access to water for 2 
hours. In contrast to palatable liquid diets, similar levels of water consumption 
were observed regardless of L-tryptophan concentrations. These data suggest that 
the anorexigenic effects of dietary L-tryptophan do not stem from an impact on 
flavour or other components of palatability of the supplemented tastants, nor do 
they arise from the suppression of thirst mechanisms. Obviously, additional 
studies are needed to rule out the possibility that L-tryptophan is nonetheless 
detectable in foods (or, e,g, affects texture, viscosity, etc), but regardless of the 
outcome of such studies, it is unlikely that its presence in ingestants promotes a 
significantly adverse gustatory response to high-tryptophan diets. 
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Ultimately, this and other experiments involving oral intake of L-tryptophan-
enriched foods strengthen the notion that ingestion of dietary L-tryptophan leads 
to a reduction in energy-driven food intake. However, administering this amino 
acid orally alongside a diet (as this diet’s component) introduces certain 
limitations in our ability to determine the relationship with intricate feeding 
mechanisms. Most notably, it is difficult to control the rate at which a meal (and, 
thus, L-tryptophan) is consumed by animals even during a well-defined feeding 
session, as the speed of consumption varies between meals, days and individuals 
despite controlled laboratory environment. Another issue with in-food delivery of 
tryptophan is that its intake (hence, its dose) mirrors consummatory behaviour 
activity instead of (preferably) preceding it. A caveat of this methodology is that 
digestion and absorption of the “carrier diet” may alter the rate at which the amino 
acid becomes available beyond the GI tract, and thus contributes to the fact that 
the effectiveness of dietary L-tryptophan relies on its cumulative effect which is 
spread over a meal time rather than occurs in an acute/”bolus” manner. Not 
surprisingly, therefore, in order to achieve a satisfactory and reliable hypophagic 
outcome, relatively high concentrations of L-tryptophan have to be used.  
 
In order to bypass the aforementioned problems associated with studying the 
effects of tryptophan by modifying its presence in a diet, the anorexigenic action 
of L-tryptophan was examined in an experimental paradigm that excludes the oral 
stage of consumption, namely in the intragastric delivery of L-tryptophan preloads. 
We chose to administer via gavage a single preload of L-tryptophan shortly before 
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mealtime, thereby ensuring that the onset of tryptophan’s action can coincide  
with the beginning of consummatory activity. The intragastric route of delivery, 
though it minimises the impact of oral mechanisms (provided they might play a 
role in the case of this particular amino acid), focuses on the influence of digestive, 
absorptive and post-absorptive processes.  
 
The intragastric infusion of L-tryptophan in energy-deprived mice given chow 
during the re-feeding phase confirmed the anorexigenic effects of L-tryptophan. 
Ng and Anderson found that a gastric preload of  600 mg/kg b. wt. decreased 
chow consumption [73]. In our set of studies, the 1200 mg/kg b. wt. dose of L-
tryptophan was sufficient to cause a moderate decrease in deprivation-induced 
chow consumption (Fig. 4). Not only did this gastric preload decrease immediate 
energy-based chow consumption, but hypophagia persisted for a period of over 24 
hours. The persistence of this anorexigenic effect and the lack of the 
compensatory intake during the subsequent night-time feeding bout suggests that 
L-tryptophan impacts long-term mechanisms driving energy balance. This is 
somewhat similar to the action of other anorexigenic amino acids. For example, 
Jordi et al. measured chow consumption for 48 hours after intragastric infusion of 
L-arginine or L-lysine [162]. Similar to L-tryptophan, these two other amino acids 
caused a long-term decrease in chow consumption, persisting for over 48 hours. 
While additional experiments are needed to determine the precise length of 
hypophagia after L-tryptophan administration, the fact that a bolus delivery of this 
amino acid has a long-term anorexigenic effect makes L-tryptophan an excellent 
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candidate for pharmacological as well as functional foods-based strategies aimed 
at curbing excessive food intake.  
 
In the context of applicability of any method or compound in anti-obesity appetite 
suppressant strategies, once has to consider the fact that the primary reason for 
overeating in the industrialised world is not hunger, but rather the 
pleasant/rewarding aspect of consumption [170]. Therefore, successful approaches 
should be able to diminish the drive to consume palatable foods irrespective of 
tastants’ energy density. In most experimental scenarios, even at the very basic 
laboratory animal level, paradigms are included that target intake for reward. 
Hence, a part of this project was also dedicated to investigating whether L-
tryptophan impacts hedonic aspects of food intake, in particular those driven by 
pleasant (usually, sweet) taste.  
 
In our experiments, non-deprived animals (thus, animals that do not have a 
negative energy balance and do not initiate consumption in order to replenish 
lacking calories) were presented with one of three palatable tastants.  These 
tastants, 0.1% saccharin solution, 10% sucrose solution and skim goat milk 
formula, shared a common denominator of a pleasant sweet taste (albeit derived 
from different sources: non-carbohydrate non-caloric sweetener; disaccharide; 
complex formula) and they were characterised by a range of energy densities 
(none in the case of saccharin and low/moderate with the sugar solution and skim 
milk). Due to the hedonic value of these ingestants, the animals consumed them 
readily despite being non-deprived. An intragastric preload of L-tryptophan 
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decreased the intake of 0.1% saccharin solution and it was effective already at a 
600 mg/kg b. wt. dose, which was lower than the one needed to reduce 
deprivation-induced chow intake (Fig. 5). A moderate decrease in the 
consumption of skim milk formula was also achieved, however, the 1200 mg/kg b. 
wt. dose had to be used (Fig. 7). Surprisingly, administration of intragastric 
preloads of L-tryptophan had no impact on the intake of 10% sucrose solution 
(Fig. 6), even at very high doses (1800 mg/kg b. wt.).  
 
As mentioned before, the animals given palatable tastants had not been food-
deprived (also, saccharin does not provide calories). Consequently, differences in 
tastant consumption likely arose due to an effect on reward-mediated food intake.  
These results imply that gastric preloads of L-tryptophan – via yet undefined 
mechanisms - decrease the intake for palatability (with the exception of sucrose). 
That the consumption of 0.1% saccharin solution (which has no energy content 
but a palatable sweet flavour) and skim milk formula (which has a moderate 
energy content and a composition rich in sweet tasting carbohydrate lactose) 
should decrease following a preload of L-tryptophan, but not 10% sucrose 
solution (which has a low energy content and a sweet flavour) suggests that 
sucrose may interact differently than other tastants with reward processes affected 
by L-tryptophan. Indeed, recent studies have demonstrated that, irrespective of 
energy content, there is variation in preference for sweet carbohydrates, and that 
sucrose appears to be a more reinforcing carbohydrate than glucose or fructose 
[171]. It suggests that the breadth and type of mechanisms underlying sucrose 
overeating may be at least partially different from those affected by other 
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carbohydrates and sweet tastants, thereby contributing to the inefficiency of select 
anorexigenic agents (including L-tryptophan) as sucrose consumption 
suppressants. While this fact does not negate the fact that L-tryptophan reduces 
feeding for reward, certain caution is warranted in defining this amino acid’s 
action as an anorexigen. L-tryptophan’s hypophagic role is conditional and it 
shows “functional interaction” with select food components (and sucrose hampers 
effectiveness of this amino acid in consumption scenarios). 
 
The data obtained in this project and by other authors [72-74, 162, 168] strongly 
indicate that L-tryptophan induces hypophagia in a much broader sense than 
previously understood. It appears that L-tryptophan decreases food intake via both 
energy-balance and reward-mediated pathways. Thus, the question arises as to 
whether neuroendocrine mechanisms known to reduce both feeding for energy 
and feeding for reward mediate this anorexigenic effect. That neural circuits 
involved in such a combined suppression of energy homeostasis- and reward-
dependent feeding are involved is in fact very much plausible. For example, the 
analysis of brain activity (using an immediate-early gene product, c-Fos, as a 
neuronal activation marker) has revealed that anorexigenic free amino acids 
activate the brainstem pathways, including the nucleus of the solitary tract (NTS) 
and the area postrema (AP). A number of metabolites of L-tryptophan are known 
to stimulate vagal afferents projecting to the AP and the NTS. Importantly, the AP 
and the NTS innervate the hypothalamus [172] as well as the ventral tegmental 
area (VTA) and nucleus accumbens (Nacc), two key reward sites [173]. Moreover, 
changes in hypothalamic c-Fos levels are affected by administration of intragastric 
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L-tryptophan [174]. One of the key hypothalamic neuropeptides that reduces 
consumption for energy and for reward is nonapeptide oxytocin, synthesised 
mainly in the paraventricular and supraoptic nuclei [175]. Oxytocin promotes 
early satiation by acting via several routes that incorporate the vagal afferent input 
as well as hypothalamic and extrahypothalamic forebrain regions: on the one hand 
it affects gastric motility/emptying and limits the volume of ingested food (an 
action also attributed to L-tryptophan supplementation [176]); on  the other, it is 
particularly effective at decreasing the intake of rewarding (palatable) tastants. 
The oxytocin system is closely intertwined via reciprocal connections with the 
reward areas, including the VTA and Nacc. Its communication with the dorsal 
vagal complex areas is also reciprocal. 
 
The results obtained in this project suggest that there is a functional link between 
the anorexigenic action of L-tryptophan and oxytocin. Not only do the actions of 
those two compounds parallel each other, but also – as shown in this thesis - the 
disturbance in oxytocin signalling prevents L-tryptophan from inducing an 
anorexigenic response. Peripheral administration of a blood-brain barrier 
penetrant oxytocin receptor antagonist (OTA), L-368,899 [177], abolished L-
tryptophan-induced hypophagia. This was achieved by injecting OTA at low 
doses (0.1 mg/kg b. wt.) – at 0.1 mg/kg, this antagonist has been shown to be 
unable to increase deprivation-induced feeding [178]. Thus, the observed effect of 
the antagonist on chow intake in hungry mice cannot be attributed to a 
hypothetical orexigenic outcome of the OTA’s action. While further studies are 
needed to expand our understanding of the functional relationship between L-
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tryptophan and oxytocin, data indicate oxytocin pathways are at least to some 
degree part of the anorexigenic neuroendocrine circuit affected by tryptophan.   
 
While the evidence base supporting the hypothesis that the anorexigenic effects of 
L-tryptophan are mediated by OT is significant, one point of contention is the 
interaction between L-tryptophan and sucrose. OT has a notable effect on sucrose 
intake which was not demonstrated by gastric preloads of L-tryptophan. This 
suggests that L-tryptophan may mediate food intake by activating a slightly 
different subset of neuronal pathways than that of OT.  
 
In sum, this project has identified L-tryptophan delivered orally or intragastrically 
as an amino acid that promotes hypophagia. It decreases consumption for energy 
as well as for reward, however appetite for sucrose seems to be resistant to 
tryptophan’s action. Anorexigenic neurohormone oxytocin appears to act as a 
central mediator of feeding termination processes triggered by L-tryptophan. 
Though the current status of research on the link between tryptophan and appetite 
is still very preliminary, it is apparent that L-tryptophan can be regarded as a 
candidate amino acid for pharmacological and functional food strategies aimed at 
curbing excessive food consumption. 
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Chapter 5: Conclusions 
 
- Dietary supplementation of L-tryptophan decreases energy-driven intake 
of palatable and nutritionally adequate goat milk-based liquid diets that serve as a 
source of calories. 
 
- A gastric preload of L-tryptophan induces a long-term (>24 h) reduction in 
deprivation-induced chow intake. 
 
- Gastric preloads of L-tryptophan reduce the reward-driven intake of 
palatable non-caloric saccharin solution and palatable goat milk formula, but not 
sucrose. 
 
- Very low doses of a BBB penetrant oxytocin receptor antagonist, L-
368,899, blocks L-tryptophan-dependent hypophagia, suggesting that oxytocin 
circuits mediate anorexigenic effects of tryptophan. 
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